A Snapshot of the Webinar “Development of a Cell-Based Assay”
Cell-based assays are usually used to represent the mechanism of action (MoA) of the administered drug. Throughout various stages of drug development, they may be used for different purposes. These include detecting the presence of neutralizing antibodies (NAbs) and evaluating a drug’s potency. In Altasciences’ webinar, “Development of a Cell-Based Assay,” Dr.
Medical Writing Expertise Is at the Heart of Your Submission
Collaboration and communication means quality documentation for your drug development program. Our Medical Writing teams collaborate constantly with our experts and yours, ensuring that very scientific document required for your study is accurate, complete, and-compliant with regulatory guidance. From initial protocol to the final clinical study report, we deliver rapidly, without compromise.
As a stand-alone solution, or part of an Altasciences study program, our Medical Writing team is ready to support you. You can work in unison with us on a Full-time equivalent (FTE)basis, or project by project, the choice is yours.
Development of a Surrogate Cerebrospinal Fluid Matrix for Quantitative Analysis of Antisense Oligonucleotides by Hybridization LC-MS/MS
A Novel Method for Performing Linearity Assessments in Whole Blood Prepared Using a Lyse/No Wash Procedure
September 2022
|
Our Altascientists are hard at work, whether it’s on your drug development projects or producing insightful scientific resources to share their knowledge with you. Catch up on what you may have missed, or revisit some highlights from the last three months. |
|
|
|
|
A Message from Our CEO to You News: Hoth Therapeutics Chooses Altasciences to Manufacture HT-TBI Award Announcement: Altasciences named finalist for Scrip Awards 2022 Audiobook Series: Listen to all issues of your favorite scientific journal, The Altascientist Scientific Journal: Issue 27—Complexities of Early Phase Ophthalmic Drug Development News: A Conversation with Chris Perkin, a Forward Thinker in the Research Space! |
|
|
|
|
On-Demand Webinar: Animal Disease Models and Overcoming Technical Challenges—Experimentally Induced Hemophilia Type A Audiobook: Altasciences’ Nonclinical Safety Testing Guide |
|
|
|
|
Blog: Five Reasons to Place Early Phase Clinical Research in Canada Quick Chat: The Makings of a CNS Center of Excellence (with Dr. Milovan) Scientific Journal: Issue 25—Flexibility in Phase I Study Timing |
|
|
|
|
Quick Chat: Complex and Customized Formulation Development (with Andrew Buis) News: Altasciences Continues Manufacturing Expansion in Philadelphia with a Client-Dedicated Building Project On-Demand Webinar: Advantages of Terminal Sterilization Over Aseptic Manufacturing |
|
|
|
|
Podcast: Microsampling—When Small Steps Lead to Big Outcomes Blog: Five Lesser-Known Uses for PCR |
|
|
|
|
Scientific Journal: Issue 26—CDISC Data Standards |
|
|
CASE STUDY—How Data Standardization Shortens Drug Approval Times
CDISC and SEND Simplify and Expedite Study Data Interpretation
Read The Altascientist and see how CDISC and SEND standards simplify and speed up analysis of your data, facilitating regulatory review and increasing your access to the power of big data. Includes two illustrative case studies and comprehensive FAQs.
Speak with an expert to learn more about our service offering.
Have five minutes? Take a look at these:
- Fact Sheet: Comprehensive Research Support Offering
- eBook: One Integrated Solution for Meeting Your Preclinical to Clinical Drug Development Needs
- Webpages:
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services.
Start Your Driving Trial Quickly—Simulators on Site
Driving simulator studies are a safe, efficient, and effective alternative to on-the-road driving trials for CNS-active drugs. The Altascientist dives into the requirements and technicalities of driving studies, and explains how driving simulation offers…
Faster study startup • Lower cost • No risk of property damage • No risk of injuries
… including a case study whose results were described as “reassuring” by the FDA.
Altasciences has conducted over 13,000 simulated drives in support of drug development.
Download as a PDF or listen to the audiobook, the choice is yours.
You may also be interested in the following:
Still Using Tablets in Your Clinical Trials? Consider Changing to a Better Option.
Accelerate Your Clinical Trials With This Dosage Form
With tablets presenting numerous drawbacks, liquid-filled capsules (LFCs) are becoming the optimal choice for clinical trials. Their benefits include:
- Ease of scalability from preclinical to clinical to commercial volumes
- Quick dose adjustments
- Faster dissolution and absorption
- Less required stability studies
LFCs are most suitable for drugs with complex formulations, low-dose requirements, poor solubility, or highly potent active pharmaceutical ingredients (APIs). Clients with such drug profiles substantially accelerated their drug development process using LFCs for early phase clinical trials, resulting in reduced costs.
Where Do We Come In?
Altasciences’ state-of-the-art cGMP manufacturing and analytical facility in Philadelphia has a team of experienced scientists to support you through your entire drug development process, from pre-formulation to clinical trials and beyond. Our advanced equipment includes cutting-edge liquid-filling, binding, and sealing machines, ensuring an impressive 97% right-first-time (RFT) batch release success rate.
Consult our resources for further details on how you can benefit from using LFCs in your clinical trials.
| eBooklet (PDF) | Infographic (PDF) | Quick Chat (Video) | Client Case Study (PDF) |
 |
 |
 |
 |
Ready to accelerate your drug development? Speak with one of our experts.
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.